Amgen Inc.

Richard V Connors

Xiaodong Wang

Xiaoqi Chen

Jeffrey Thomas Mihalic

Zhihua Ma

David John Kopecky

Jeffrey Deignan

Julie Anne Heath

Steven H Olson

Zice Fu

Julio Cesar Medina

Lawrence R McGee

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Su-Jen Lai

Nobuko Nishimura

Ning Chen

Frank Kayser

Xiaohui Du

Alan C Cheng

Mikkel V Debenedetto

Kevin Chao Yang

Matthew R Kaller

Ted Charles Judd

Daniel B Horne

Simon J Hedley

Gayathri Swaminath

Wen-Chen Yeh

Yinhong Chen

Aarif Yusuf Khakoo

Robert P Farrell

John Eksterowicz

Zhihong Li

Jiasheng Fu

Benjamin Fisher

Dustin L McMinn

James S Harvey

Pingchen Fan

Daqing Sun

Xuelei Yan

Michael G Johnson

Rajiv Sharma

Yosup Rew

Felix Gonzalez Lopez De Turiso

Brian M Fox

Michael D Bartberger

Hilary Plake Beck

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Kexue Li

Darin J Gustin

Joel McIntosh

Yihong Li

Kang Dai

Philip M Roveto

Malgorzata Wanska

Ming Yu

Jonathan Dante Low

Jiwen Liu

Brian Stuart Lucas

Yingcai Wang

Lars V Heumann

XianYun Jiao

Michael W Gribble, Jr

Xin Huang

SuJen Lai

Jiang Zhu

Jeffrey T Mihalic

Julio C Medina

Matthew Irvine Brown

Juan Carlos Jaen

Leping Li

Xi Chen

Kevin Yang

Michael J Schmitt

Mike Elias Lizarzaburu

Stephen J Shuttleworth

Yong-Jae Kim

Ying Fu

Christine Weathers

Dai Kang

Lawrence R Mcgee

Joel Mcintosh

Julie A Heath

David J Kopecky

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

Mesa, AZ, United States of America

Richard V Connors